2-溴-5-氟硫代苯甲醚 | 147460-43-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 2-溴-5-氟硫代苯甲醚
• 英文名称: 1-bromo-4-fluoro-2-(methylsulfanyl)benzene
• 英文别名: 1-bromo-4-fluoro-2-methylsulfanyl-benzene；1-bromo-4-fluoro-2-methylsulfanylbenzene；1-Bromo-4-fluoro-2-methylthiobenzene；2-Bromo-5-fluorothioanisole
• CAS: 147460-43-3
• 化学式: C₇H₆BrFS
• 分子量: 221.093
• InChiKey: JPRNOVPCJUSIBE-UHFFFAOYSA-N

物化性质

• 沸点：
  219.8±30.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2930909090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-5-fluorothioanisole
Synonyms: (2-Bromo-5-fluorophenyl)(methyl)sulfane

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-fluorothioanisole
CAS number: 147460-43-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6BrFS
Molecular weight: 221.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-5-氟硫代苯甲醚 在 titanium(IV) isopropylate 、 三乙基硅烷 、 叔丁基过氧化氢 、 氢氧化钾 、 正丁基锂 、 D-(-)-酒石酸二乙酯 、 三氟乙酸 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 水 为溶剂， 生成 3-cyano-N-[(2S)-2-(3,4-dichlorophenyl)-4-[4-(5-fluoro-2-methylsulfinylphenyl)piperidin-1-yl]butyl]-N-methylnaphthalene-1-carboxamide
  参考文献：
  名称：

  Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity

  摘要：

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

  DOI：

  10.1021/jm020094i
• 作为产物：
  描述：

  2-溴-5-氟苯酚 在 三乙烯二胺 、 氢氧化钾 、 potassium carbonate 、 N,N-二乙基苯胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-溴-5-氟硫代苯甲醚
  参考文献：
  名称：

  Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity

  摘要：

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

  DOI：

  10.1021/jm020094i

文献信息

• [EN] IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS<br/>[FR] DERIVES D'IMIDAZO-PYRIDINE UTILISES EN TANT QUE LIGANDS POUR LES RECEPTEURS GABA
  申请人：MERCK SHARP & DOHME

  公开号：WO2003099816A1

  公开（公告）日：2003-12-04

  A class of 8-fluoro-3-phenylimidazo[1,2-a]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group, or by a pyrrolidinonyl group, which is directly attached or bridged by an oxygen atom or by a -NH- or -OCH2- linkage, being selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

  一类8-氟-3-苯基咪唑并[1,2-a]吡啶衍生物，通过苯环的间位被一个可选择取代的芳基或杂环芳基团，或者通过一个吡咯烷基团取代，该吡咯烷基团直接连接或通过氧原子或-NH-或-OCH2-键连接，作为GABAA受体的选择性配体，特别是对其α2和/或α3和/或α5亚基具有高亲和力，因此在治疗和/或预防中枢神经系统的不良状况，包括焦虑、惊厥和认知障碍方面具有益处。
• [EN] SUBSTITUTED TRIAZOLOPYRIDINES<br/>[FR] TRIAZOLOPYRIDINES SUBSTITUÉES
  申请人：BAYER PHARMA AG

  公开号：WO2011157688A1

  公开（公告）日：2011-12-22

  The present invention relates to substituted triazolopyridine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds.

  本发明涉及通式（I）的取代三唑吡啶化合物，其中R1、R2、R3、R4和R5如描述和索赔中所述，以及制备所述化合物的方法，包括所述化合物的药物组合物和组合物，用于制造用于治疗或预防细��生长、增殖和/或存活失控疾病的药物组合物以及用于制备所述化合物的中间化合物的用途。
• [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS<br/>[FR] MODULATEURS SELECTIFS DU RECEPTEUR DES OESTROGENES POUR LE TRAITEMENT DE SYMPTOMES VASOMOTEURS
  申请人：LILLY CO ELI

  公开号：WO2005073204A1

  公开（公告）日：2005-08-11

  The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.

  本发明涉及一种公式I或Ia的选择性雌激素受体调节剂：(I) (Ia)；或其药物酸加成盐；用于治疗血管舒缩症状，尤其是热潮红、夜间出汗以及影响绝经前后妇女的其他症状。
• [EN] ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES<br/>[FR] ANALOGUES D'HEXAHYDROPYRIMIDINE ANTIPALUDIQUES
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2019192992A1

  公开（公告）日：2019-10-10

  The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-l,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria.

  该应用涉及一系列以芳基氨基苯基或杂环芳基氨基苯基取代的2-亚氨基-6-甲基六氢嘧啶-4-酮衍生物和3-亚氨基-5-甲基-1,2,4-噻二唑啉-1,1-二氧化物衍生物的化合物，其化学式为(I)。这些化合物是对抗寄生于人体血液中的疟原虫Plasmodium falciparum生长和传播的有效抑制剂，因此可用作治疗疟疾的药物。
• Benzimidazoles
  申请人：FISONS plc

  公开号：EP0526033A1

  公开（公告）日：1993-02-03

  There are described compounds of formula I,    wherein one of R¹ and R² represents halogen or alkyl C₁₋₆, and the other represents hydrogen,    R³ represents alkyl C₁₋₆,    and pharmaceutically acceptable salts thereof. Processes for making the compounds and pharmaceutical compositions containing them, e.g. for the treatment of conditions in which gastric acid has a pathological role, are also disclosed.

  已描述了化合物的化学式 I，其中 R¹ 和 R² 中的一个代表卤素或烷基 C₁₋₆，另一个代表氢，R³ 代表烷基 C₁₋₆，以及其药用盐。还公开了制备这些化合物和含有它们的药物组合物的方法，例如用于治疗胃酸在病理作用中起作用的情况。